Literature DB >> 32628976

SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype.

Naoki Yamamoto1, Yasuo Ariumi2, Nao Nishida3, Rain Yamamoto4, Georg Bauer5, Takashi Gojobori6, Kunitada Shimotohno7, Masashi Mizokami8.   

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The relentless spread and pathogenicity of the virus have become a global public health emergency. One of the striking features of this pandemic is the pronounced impact on specific regions and ethnic groups. In particular, compared with East Asia, where the virus first emerged, SARS-CoV-2 has caused high rates of morbidity and mortality in Europe. This has not been experienced in past global viral infections, such as influenza, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) and is unique to SARS-CoV-2. For this reason, we investigated the involvement of genetic factors associated with SARS-CoV-2 infection with a focus on angiotensin-converting enzyme (ACE)-related genes, because ACE2 is a receptor for SARS-CoV-2. We found that the ACE1 II genotype frequency in a population was significantly negatively correlated with the number of SARS-CoV-2 cases. Similarly, the ACE1 II genotype was negatively correlated with the number of deaths due to SARS-CoV-2 infection. These data suggest that the ACE1 II genotype may influence the prevalence and clinical outcome of COVID-19 and serve as a predictive marker for COVID-19 risk and severity.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACE1 I/D polymorphism; ACE1 II genotype; COVID-19; Ethnicity; Mortality; Prevalence; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32628976     DOI: 10.1016/j.gene.2020.144944

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  56 in total

1.  Are angiotensin converting enzyme (ACE1/ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A single-center cohort study.

Authors:  Serdal Baştuğ; Büşranur Çavdarlı; Aliye Baştuğ; İrfan Şencan; Ebru Tunçez; Esra Yakışık Çakır; Nizamettin Kemirtlek; Cihad Sakar; Deniz Erdem; Gülay Güleç Ceylan; Işıl Özkoçak Turan; Sümeyye Kazancıoğlu; Hürrem Bodur
Journal:  Anatol J Cardiol       Date:  2022-02       Impact factor: 1.596

Review 2.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 3.  Effects of selected inherited factors on susceptibility to SARS-CoV-2 infection and COVID-19 progression.

Authors:  J A Hubacek
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

4.  Could the CCR5-Delta32 mutation be protective in SARS-CoV-2 infection?

Authors:  N Starcevic Cizmarevic; M Kapovic; D Roncevic; S Ristic
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

5.  Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis.

Authors:  Cristine Dieter; Letícia de Almeida Brondani; Cristiane Bauermann Leitão; Fernando Gerchman; Natália Emerim Lemos; Daisy Crispim
Journal:  PLoS One       Date:  2022-07-06       Impact factor: 3.752

6.  A systems biology analysis of protein-protein interaction of digestive disorders and Covid-19 virus based on comprehensive gene information.

Authors:  Arghavan Hosseinpouri; Mostafa Rezaei-Tavirani; Elham Gholizadeh; Reza Karbalaei
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

Review 7.  p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).

Authors:  Daniela Milani; Lorenzo Caruso; Enrico Zauli; Adi Mohammed Al Owaifeer; Paola Secchiero; Giorgio Zauli; Donato Gemmati; Veronica Tisato
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

8.  CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects.

Authors:  J A Hubacek; L Dusek; O Majek; V Adamek; T Cervinkova; D Dlouha; J Pavel; V Adamkova
Journal:  Physiol Res       Date:  2021-03-17       Impact factor: 1.881

Review 9.  Does Genetic Predisposition Contribute to the Exacerbation of COVID-19 Symptoms in Individuals with Comorbidities and Explain the Huge Mortality Disparity between the East and the West?

Authors:  Naoki Yamamoto; Rain Yamamoto; Yasuo Ariumi; Masashi Mizokami; Kunitada Shimotohno; Hiroshi Yoshikura
Journal:  Int J Mol Sci       Date:  2021-05-08       Impact factor: 5.923

10.  ACE I/D polymorphism and epidemiological findings for COVID-19: One year after the pandemic outbreak in Europe.

Authors:  Smiljana Ristić; Sanja Dević Pavlić; Sergej Nadalin; Nada Starčević Čizmarević
Journal:  J Infect       Date:  2021-06-16       Impact factor: 38.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.